Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant

• Published in: Molecular therapy Vol. 32; no. 12; pp. 4448 - 4466
• Main Authors: Laghlali, Gabriel, Wiest, Matthew J., Karadag, Dilara, Warang, Prajakta, O’Konek, Jessica J., Chang, Lauren A., Park, Seok-Chan, Yan, Vivian, Farazuddin, Mohammad, Janczak, Katarzyna W., García-Sastre, Adolfo, Baker, James R., Wong, Pamela T., Schotsaert, Michael
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 04.12.2024; American Society of Gene & Cell Therapy
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Vaccine - administration & dosage; Administration, Intranasal; Animals; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Female; Humans; Immunity, Mucosal; Immunization, Secondary; Injections, Intramuscular; intranasal vaccination; Mice; mRNA vaccines; mRNA Vaccines - immunology; mucosal adjuvants; mucosal immunization; Original; prime/pull; SARS-Cov-2; SARS-CoV-2 - immunology; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; tissue-resident memory T cells; Vaccination - methods; mucosal immunization; SARS-Cov-2; intranasal vaccination; prime/pull; mRNA vaccines; mucosal adjuvants; tissue-resident memory T cells

Current COVID-19 mRNA vaccines delivered intramuscularly (IM) induce effective systemic immunity, but with suboptimal immunity at mucosal sites, limiting their ability to impart sterilizing immunity. There is strong interest in rerouting immune responses induced in the periphery by parenteral vaccin...